- Global Pharma News & Resources

Mometasone Furoate Global Market Report 2022: Increasing Worldwide Prevalence of Asthma Fueling Growth -

DUBLIN--(BUSINESS WIRE)--The "Mometasone Furoate Market, by Dosage Form, by Indication, by Route Of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to's offering.

Mometasone furoate topical is effective at reducing the redness, itching, swelling, and other pain caused by several skin conditions. Mometasone furoate is a corticosteroid drug also used to treat asthma and it is an effective treatment for a variety of skin allergies as well as other allergic conditions like hay fever and allergic rhinitis.

Market Dynamics

Increasing prevalence of asthma worldwide is expected to witness significant growth in forecast period. For instance, according to the World Health Organization (WHO), in 2019, 455 000 individuals died from asthma and an estimated 262 million people were affected by asthma worldwide. Asthma is widely misdiagnosed and poorly managed, particularly in low- and middle-income countries. In most severe cases, asthma can be fatal.

Increasing product launches and approvals by market players are expected to drive growth of the global mometasone furoate market over the forecast period. For instance, in April 2017, Amneal Pharmaceuticals LLC, a U.S.-based, publicly traded generics and specialty pharmaceutical company launched Mometasone furoate nasal spray, the first pharmaceutical product that Amneal Pharmaceuticals LLC had produced in spray form. Nasonex is therapeutic equivalent of mometasone furoate and is offered in 50 mcg/spray strength.

Increasing research and development activities related to mometasone furoate are expected to drive growth of market over the forecast period. For instance, according to an article published in Medicine, medical journal, in December 2019, a study was performed on patients with head and neck squamous cell carcinoma (HNSCC) to check efficacy of local application of mometasone furoate in reducing acute radiation dermatitis (ARD) in China.

Patients were divided into two groups, test groups and control groups. The patients in test groups were given mometasone furoate once daily from the start of their radiotherapy until the test side skin acquired ARD lesions, and patients in control groups, were given no treatment at all. The study showed that, mometasone furoate inunction after high dose radiotherapy can prevent acute radiation dermatitis (ARD).

Key features of the study:

  • This report provides an in-depth analysis of the global mometasone furoate market, market size (US$ Million), and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global mometasone furoate market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
  • Insights from this report would allow marketers and the management authorities of the companies to make an informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics.
  • The global mometasone furoate market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global mometasone furoate market

Detailed Segmentation:

Global Mometasone Furoate Market, By Dosage form:

  • Nasal Spray
  • Cream
  • Ointment
  • Inhalers
  • Others (Topical Solutions, etc.)

Global Mometasone Furoate Market, By Indication:

  • Inflammatory Skin Disorders
  • Asthma
  • Allergic rhinitis
  • Others (Hay Fever, etc.)

Global Mometasone Furoate Market, By Route of Administration:

  • Nasal Administration
  • Topical
  • Oral

Global Mometasone Furoate Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Mometasone Furoate Market, By Region:

  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • Central Africa
  • North Africa

Company Profiles

  • Cipla
  • Teva Pharmaceuticals
  • Glenmark Pharmaceuticals
  • AdvaCare Pharma
  • Medlab Pharmaceuticals Private Limited
  • Dermocare Laboratories
  • Iva Healthcare Private Limited
  • Unilab Chemicals & Pharmaceuticals Pvt Ltd
  • Organon group of companies
  • Cosette Pharmaceuticals
  • Taro Pharmaceutical Industries Ltd.
  • Hikma Pharmaceuticals.

Key Topics Covered:

1. Research Objectives and Assumptions

2. Market Overview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Mometasone Furoate Market - Impact of Coronavirus (Covid-19) Pandemic

5. Global Mometasone Furoate Market , By Dosage Form, 2017-2030 (US$ Million)

6. Global Mometasone Furoate Market , By Indication, 2017-2030 (US$ Million)

7. Global Mometasone Furoate Market , By Route of Administration , 2017-2030 (US$ Million)

8. Global Mometasone Furoate Market , By Distribution Channel, 2017-2030 (US$ Million)

9. Global Mometasone Furoate Market , By Region, 2017-2030 (US$ Million)

10. Competitive Landscape

11. Section

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 08-Dec-2022